RE: RE: GENF has SIRT6..... Worth 100 bagger!18 Jul 2025 12:34
If Genflow secures patents covering SIRT6-based therapies, it becomes a first-mover in the listed longevity space in Europe — a sector with serious tailwinds. Even rumors of allowance or national phase grants in the EU, US, or Asia could trigger rerates from these suppressed levels.
FIRST MOVER ADVANTAGE IS HUGE. Just look at how SWC responded to 1st mover advantage
€4m non dilutive essentially free money from The Goverment
This should valued minimum £20m
The IP alone is worth far more